News & Events – Page 16 – Sumitovant

Select Company

April 03, 2019Enzyvant’s Investigational Regenerative Treatment (RVT-802) for Congenital Athymia to be Discussed in Symposium, Platform Presentation and Poster Session at Clinical Immunology Society Meeting
March 27, 2019Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia
March 21, 2019Enzyvant’s Investigational Farber Disease Enzyme Replacement Therapy, RVT-801, Receives FDA Fast Track and Rare Pediatric Disease Designations
March 19, 2019Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder
March 18, 2019Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder
March 07, 2019Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference
March 06, 2019Urovant Sciences Appoints James Robinson to its Board of Directors
March 05, 2019Myovant Sciences to Present at Upcoming Investor Conferences
February 22, 2019Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital
February 21, 2019Enzyvant Appoints Industry Veteran Rachelle Jacques as Chief Executive Officer
« Previous 1 … 14 15 16 17 Next »